Diagnostic value of the stimulating growth factor ST2 during hospitalization for myocardial infarction


Aim. To determine the concentration of the stimulating growth factor ST2 and its relationship to the clinical course of myocardial infarction (MI) over time during hospitalization. Subjects and methods. Eighty-eight MI patients whose mean age was 59±8.36 years were examined. On days 1 and 12 of MI, the serum levels of ST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were determined by ELISA. A control group consisted of 30 people. Results. On day 1 of hospitalization for MI, the concentrations of ST2 and NT-proBNP were higher 2.4 and 4.5 times, respectively, than those in the controls; by day 12, there was a statistically significant decrease in the level of ST2 while that of NT-proBNP was unchanged. During hospitalization, the investigators recorded MI complications, according to which the patients were divided into favorable and unfavorable MI groups. On day 1 of hospitalization, the level of ST2 in the patients with unfavorable MI was twice higher than in those with favorable MI and 3.7 times higher than in the control group. On day 12, both favorable and unfavorable MI groups showed a reduction in the level of the marker. On day 1 of MI, the concentration of NT-proBNP in the patients with a poor prognosis was 6.8 times greater than in the controls and 1.8 times more than in the patients with a good prognosis. On day 12, NT-proBNP levels remained elevated in both groups. Logistic regression analysis revealed that the determination of ST2 in combination with NT-proBNP increased their diagnostic significance (odds ratio, 1.92; 95% CI, 1.7—3.2; area under characteristic curve, 0.89; p=0.004). Conclusion. The level of ST2 was a more sensitive indicator of hospitalization for MI than that of NT-proBNP. The combined use of ST2 and NT-proBNP was found to have a high diagnostic sensitivity and specificity.


  1. Opie L, Commerford P, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. Controvers. Cardiol. 2006;367:33-44. doi: 10.1016/s0140-6736(06)68074-4.
  2. Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Morkrid L, Edvardsen T. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am Heart J. 2013;165(5):716-724. doi: 10.1016/j.ahj.2013.02.008.
  3. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano PA. Novel Cardiac Bio-Marker: ST2: A Review. Molecules. 2013;18;15314-15328. doi: 10.3390/molecules181215314.
  4. Барбараш О.Л., Усольцева Е.Н., Шафранская К.С., Зыков М.В., Груздева О.В., Поликутина О.М., Кашталап В.В. Возможность использования n-терминального фрагмента мозгового натрий-уретического пропептида как маркера мультифокального атеросклероза у больных инфарктом миокарда с подъемом сегмента ST. Российский кардиологический журнал. 2012;3(95):12-18.
  5. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013;24(7):286-289. doi: 10.5830/CVJA-2013-055.
  6. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551-2555. doi: 10.4049/jimmunol.179.4.2551.
  7. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Pina IL, Zannad F, Kraus WE, O’Connor CM. Soluble ST2 in ambulatory patients with heart failure association with functional capacity and long-term qutcomes. Circulation: Heart Fail. 2013;6:1172-1179. doi: 10.1161/CIRCHEARTFAILURE.113.000207.
  8. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-2190. doi: 10.1161/01.cir.0000127958.21003.5a.
  9. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA. Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clin Chem. 2012;58(1):257-266. doi: 10.1373/clinchem.2011.173369.
  10. He Q, Wang D, Yang X, Carretero OA, LaPointe MC. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. Am J Physiol Heart Circ Physiol. 2001;280:368-376.
  11. Mathewkutty S, Sethi SS, Aneja A, Shah K, Iyengar RL, Hermann L, Khakimov S, Razzouk L, Esquitin R, Vedanthan R, Benjamin TA, Grace M, Nisenbaum R, Ramanathan K, Ramanathan L, Chesebro J, Farkouh ME. Biomarkers after risk stratification in acute chest pain (from the BRIC Study). Am J Cardiol. 2013;111(4):493-498. doi: 10.1016/j.amjcard.2012.10.032.
  12. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-840. doi: 10.1038/nrd2660.
  13. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936-1944. doi: 10.1161/circulationaha.107.728022.
  14. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549. doi: 10.1172/jci30634
  15. Каретникова В.Н., Груздева О.В., Барбараш О.Л. Роль маркеров воспаления в оценке прогноза у больных инфарктом миокарда с подъемом сегмента st в сочетании с нарушениями углеводного обмена. Кардиология. 2012;52(8):20-26.
  16. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961-2966. doi: 10.1161/01.cir.0000038705.69871.d9.



Abstract - 71

PDF (Russian) - 16


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Gruzdeva O.V., Akbasheva O.E., Uchasova E.G., Dyleva Y.A., Fedorova N.V., Karetnikova V.N., Kashtalap V.V., Barbarash O.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies